Curcumin is a polyphenolic compound derived from Curcumin longa L. There is growing body of data showing the antitumor effect of curcumin in different cancers; however, the molecular mechanism underlying of this inhibition in breast cancer is still remained to be elucidated. Here we investigated the antitumor activity of curcumin alone or in combination with paclitaxel or doxorubicin in MCF-7 cells in monolayer cell cultures and spheroids models. Moreover, the cytotoxic activity of three different forms of curcumin (phytosomal), phospholipidated curcumin, amorphous curcumin and turmeric oleoresin were evaluated, compared to unformulated curcumin.
The antiproliferative activity of 4 different forms of curcumin was assessed in monolayer and spheroid models of MCF-7 cells. The cell cycle modulation and migratory behaviors of the cells were determined by FACS and migration assay before and after treatment with curcumin. The expression levels of survivin, CyclinD1, MMP3, MMP9, P65, P21, Nf-kB, and E-cadherin were studied by quantitative RT–PCR and/or western blot.
Ccurcumin suppressed cell growth in MCF-7 cells at 110uM IC50 value. The median drug-effect analysis showed a slight-to-moderate synergism with CI values of 0.8. Curcumin was able to reduce the invasiveness of MCF-7, compared to control cells. Moreover, curcumin inhibited the tumor growth in MCF-7 cells, although this inhibition was more pronounced with amorphous/phospholipidated curcumin. Additionally, curcumin significantly (P
We demonstrated the antitumor activity of curcumin and its curcumin oleoresin in a breast cancer cell line, supporting further investigations on the therapeutic potential of this novel anticancer agent in in vivo models.
Clinical trial indentification
Legal entity responsible for the study
Mashhad University of Medical Sciences
All authors have declared no conflicts of interest.